This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Daniel Rader, MD
Seymour Gray Professor of Molecular Medicine, Perelman School of Medicine at University of Pennsylvania


Dr. Rader is the Seymour Gray Professor of Molecular Medicine and Chair of the Department of Genetics at the Perelman School of Medicine at the University of Pennsylvania, where he also serves as Chief of the Divisions of Human Genetics in the Departments of Medicine and Pediatrics. 

Dr. Rader attended the Medical College of Pennsylvania in Philadelphia and trained in internal medicine at Yale-New Haven Hospital, where he served as chief resident.  He trained in lipidology, human genetics, and translational research at the National Institutes of Health, and was recruited to the faculty at Penn in 1994.

Dr. Rader’s research has focused on the human genetics and physiology of lipid metabolism and cardiometabolic disease, as well as the translational implications for novel therapeutic approaches.  He ‘rescued’ an abandoned molecule that reduces cholesterol and led the successful development and regulatory approval of this compound as a novel therapeutic for patients with a genetic form of severely elevated cholesterol.  He is known for his original work in the metabolism and function of HDL.  He has led pioneering studies of novel biological pathways in lipid metabolism and cardiometabolic disease. Dr. Rader founded and directs the Penn Medicine BioBank, an integrated resource to support human genetics and translational research, and he is a champion of genomic medicine applied to prevention. He has been a founder of several start-up biotech companies related to his work.

Dr Rader sees patients with lipid disorders and has been regularly recognized by Top Doctors in Philadelphia. He has been a recipient of several national and international research awards, including the Award for Outstanding Work in Science as Related to Medicine from the American College of Physicians and the Research Achievement Award from the American Heart Association.  He has been elected to the National Academy of Medicine and the American Academy of Arts and Sciences.

Agenda Sessions

  • A Therapeutic Antibody to ApoC3 for Treatment of Hypertriglyceridemia